» Articles » PMID: 11777617

Direct Evidence That Prostate Tumors Show High Sensitivity to Fractionation (low Alpha/beta Ratio), Similar to Late-responding Normal Tissue

Overview
Specialties Oncology
Radiology
Date 2002 Jan 5
PMID 11777617
Citations 164
Authors
Affiliations
Soon will be listed here.
Abstract

Purpose: A direct approach to the question of whether prostate tumors have an atypically high sensitivity to fractionation (low alpha/beta ratio), more typical of the surrounding late-responding normal tissue.

Methods And Materials: Earlier estimates of alpha/beta for prostate cancer have relied on comparing results from external beam radiotherapy (EBRT) and brachytherapy, an approach with significant pitfalls due to the many differences between the treatments. To circumvent this, we analyze recent data from a single EBRT + high-dose-rate (HDR) brachytherapy protocol, in which the brachytherapy was given in either 2 or 3 implants, and at various doses. For the analysis, standard models of tumor cure based on Poisson statistics were used in conjunction with the linear-quadratic formalism. Biochemical control at 3 years was the clinical endpoint. Patients were matched between the 3 HDR vs. 2 HDR implants by clinical stage, pretreatment prostate-specific antigen (PSA), Gleason score, length of follow-up, and age.

Results: The estimated value of alpha/beta from the current analysis of 1.2 Gy (95% CI: 0.03, 4.1 Gy) is consistent with previous estimates for prostate tumor control. This alpha/beta value is considerably less than typical values for tumors (> or =8 Gy), and more comparable to values in surrounding late-responding normal tissues.

Conclusions: This analysis provides strong supporting evidence that alpha/beta values for prostate tumor control are atypically low, as indicated by previous analyses and radiobiological considerations. If true, hypofractionation or HDR regimens for prostate radiotherapy (with appropriate doses) should produce tumor control and late sequelae that are at least as good or even better than currently achieved, with the added possibility that early sequelae may be reduced.

Citing Articles

Biochemical response to neoadjuvant hormonal therapy predicts long-term prostate cancer survival outcomes after high-dose-rate brachytherapy with external beam radiotherapy.

Makino T, Sakurai T, Takamatsu S, Kano H, Naito R, Iwamoto H Sci Rep. 2025; 15(1):5118.

PMID: 39934343 PMC: 11814089. DOI: 10.1038/s41598-025-89771-x.


Hypofractionated image-guided radiotherapy with 70 Gy in 28 fractions for prostate cancer confined to the pelvis: a single institute experience in Taiwan.

Mu H, Chi M, Ko H, Juang G, Hwang T, Chi K BMC Urol. 2025; 25(1):12.

PMID: 39849412 PMC: 11756135. DOI: 10.1186/s12894-024-01661-y.


Prognostic significance of the mEPE score in intermediate-risk prostate cancer patients undergoing ultrahypofractionated robotic SBRT.

Mose L, Loebelenz L, Althaus A, Ahmadsei M, Mathier E, Broemel I Strahlenther Onkol. 2025; .

PMID: 39809998 DOI: 10.1007/s00066-024-02355-y.


Stereotactic Body Therapy for Urologic Cancers-What the Urologist Needs to Know.

Coles-Black J, Rahman A, Siva S, Ischia J, Perera M, Bolton D Life (Basel). 2025; 14(12.

PMID: 39768390 PMC: 11678295. DOI: 10.3390/life14121683.


Dosimetric evaluation of ultrafractionated dose escalation with simultaneous integrated boost to intraprostatic lesion using 1.5-Tesla MR-Linac in localized prostate cancer.

Onal C, Arslan G, Yavas C, Efe E, Yavas G Rep Pract Oncol Radiother. 2024; 29(1):10-20.

PMID: 39165591 PMC: 11333072. DOI: 10.5603/rpor.99358.